HOLOGIC



SARS-CoV-2 Assays

Fully automated, high-throughput assays for the detection of SARS-CoV-2.

Accurate and fully automated testing is critical in the fight against the threat of SARS-CoV-2 and key to quickly identifying who's infected and subsequently helping alleviate the spread of this novel virus.

Challenges facing laboratories

Huge sample demand, underscoring the need for high-throughput molecular automation.¹



Requirement to deliver rapid results to patients and clinicians.¹



Uncertainty around future and continued testing needs for SARS-CoV-2 and other respiratory viruses.²⁻³

The power to choose. The potential to grow. The flexibility and scalability of the Panther[®] system provides accessibility to two molecular SARS-CoV-2 assays allowing labs to:

- Meet the urgent need for highthroughput and fully-automated testing delivering more than 1000 test results in 24 hours.*4
- Detect SARS-CoV-2 to guide patient management and mitigate the spread of infection.⁵⁻⁶
- Detect and differentiate
 SARS-CoV-2 and influenzas
 A & B during respiratory season.

Aptima[®]



Supporting laboratories during the global pandemic

The Aptima® SARS-CoV-2 and Aptima SARS-CoV-2/Flu assays are designed for the Hologic Panther system. The assays can be run alongside current infectious disease, women's health and virology assays enabling laboratories to unlock the free capacity on their existing Panther systems.

Delivering the performance and flexibility you need

Aptima[®] SARS-CoV-2 assay on the Panther[®] system⁵



Aptima[®] SARS-CoV-2 Assay

For the qualitative detection of SARS-CoV-2 from individuals meeting COVID-19 clinical and/or epidemiological criteria as well as individuals without symptoms or other reasons to suspect COVID-19 infection.

Applicable specimen types include:

- Nasopharyngeal, nasal and oropharyngeal swab specimens collected in UTM/VTM, saline, Liquid Amies or Aptima Specimen Transport Medium
- · Saliva specimens in Minimum Essential Medium
- Pooled samples containing up to 5 individual saliva samples or upper respiratory swab specimens

Aptima SARS-CoV-2/Flu assay on the Panther system⁶



For the qualitative detection and differentiation of SARS-CoV-2, influenza A virus and influenza B virus from individuals suspected of respiratory viral infection consistent with COVID-19.

Aptima[®] sars-CoV-2/Flu

Applicable specimen types include:

 Nasopharyngeal and nasal swab specimens collected in UTM/VTM, saline or Aptima Specimen Transport Medium

Assay product description	Catalogue number	Kit quantity	Additional notes
Aptima SARS-CoV-2 assay kit	PRD-06419	250 tests	Assay reagent kit only
Aptima SARS-CoV-2 assay controls kit	PRD-06420	5 sets	Order separately as needed

Assay

Assay product description	Catalogue number	Kit quantity	Additional notes
Aptima SARS-CoV-2/Flu assay kit	PRD-06815	250 tests	Assay reagent kit only
Aptima SARS-CoV-2/Flu assay controls kit	PRD-06816	5 sets	Order separately as needed

Additional respiratory assays for the qualitative detection and differentiation of SARS-CoV-2, influenza A, influenza B, respiratory syncytial virus, adenovirus, human metapneumovirus, rhinovirus, parainfluenza and Bordetella are available on the Panther Fusion®, please refer to the Panther Fusion catalogue. Please note that a Panther Fusion module will be required to run these assays.

* Number of actual test results per day may vary based on individual lab practices and workflows.

References: 1. Vandenberg, O., Martiny, D., Rochas, O. et al. Considerations for diagnostic COVID-19 tests. Nat Rev Microbiol 19, 171–183 (2021). https://doi.org/10.1038/s41579-020-00461-z. Accessed August 2022. 2. Messacar K, Baker RE, Park SW, et al. Preparing for uncertainty: endemic paediatric viral illnesses after COVID-19 pandemic disruption. Lancet. 2022 Jul 14:S0140-6736(22)01277-6. doi: 10.1016/S0140-6736(22)01277-6. Epub ahead of print. Erratum in: Lancet. 2022 Jul 19; PMID: 35843260; PMID: Dis9843260; PMID: PMC9282759. 3. Baker RE, Park SW, yang W, et al. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. Proc Natl Acad Sci U S A. 2020 Dec 11/17(48):3054736553. doi: 10.1016/S0140-4736523. doi: 10.1016/S0140-4736523. doi: 10.1016/S0140-473652. Doi: 10.1016/S014

CE REP Hologic BV, Da Vincilaan 5, 1930 Zaventern, Belgium. EC REP details wherever applicable

Diagnostic Solutions | Hologic.com | euinfo@hologic.com

SS-00955-EUR-EN Rev 004 © 2022 Hologic, Inc. All rights reserved. Hologic, Aptima, Panther, Panther Fusion and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. All other trademarks, registered trademarks and product names are the property of their respective owners. This information is intended for medical professionals and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through vestises, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your Hologic representative or write to **euinfo@hologic.com**.